Skip to Content

AbbVie Inc ABBV

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

AbbVie’s Next Generation Drugs Are Poised to Help Mitigate Upcoming Humira Biosimilar Pressures

Damien Conover, CFA Sector Director

Analyst Note

| Damien Conover, CFA |

After a deep dive review of several of AbbVie’s current and pipeline products, we have increased our projections for several drugs leading to a fair value estimate increase to $114 from $108. We continue to view the company with a narrow moat based on strong support from its pipeline that should offset pressures to the approaching U.S. Humira biosimilar competition in 2023.

Read Full Analysis

Company Profile

Business Description

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The company's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

Contact
1 North Waukegan Road
North Chicago, IL, 60064-6400
T +1 847 932-7900
Sector Healthcare
Industry Drug Manufacturers - General
Most Recent Earnings Sep 30, 2021
Fiscal Year End Dec 31, 2021
Stock Type High Yield
Employees 50,000

Related